Efficacy and Safety of Zuojin Pill for the Treatment of Chronic Nonatrophic Gastritis: A Randomized Active-Controlled Clinical Trial

Table 3

Subgroup comparison based on Helicobacter pylori infection after treatment (mean ± SD).

Variables	Zuojin pill	Marzulene-S granule	value
Helicobacter pylori infection positive	N = 15	N = 18
Red plaques	1.40 ± 1.12	1.56 ± 0.92	0.665
Erosion	2.07 ± 0.80	2.11 ± 0.83	0.877
Hemorrhage	0.53 ± 0.83	0.67 ± 0.77	0.636
Bile reflux	0.47 ± 0.74	0.83 ± 1.04	0.263
Chronic inflammation	1.87 ± 0.99	1.78 ± 0.88	0.786
Active chronic inflammation	1.27 ± 1.10	2.06 ± 0.94	0.033
Abdominal distension	1.00 ± 0.84	1.39 ± 0.70	0.157
Belching	0.27 ± 0.70	0.78 ± 1.00	0.107
Nausea and vomiting	0.54 ± 0.92	0.39 ± 0.78	0.627
Loss of appetite	0.40 ± 0.63	0.83 ± 0.78	0.095
Helicobacter pylori infection negative	N = 19	N = 16
Red plaques	0.95 ± 0.70	1.69 ± 1.01	0.016
Erosion	1.63 ± 1.01	1.62 ± 0.72	0.980
Hemorrhage	0.26 ± 0.65	0.38 ± 0.62	0.609
Bile reflux	0.16 ± 0.50	0.38 ± 0.88	0.369
Chronic inflammation	1.16 ± 0.83	2.06 ± 0.93	0.005
Active chronic inflammation	1.32 ± 1.16	1.56 ± 1.03	0.514
Abdominal distension	0.58 ± 0.69	1.19 ± 0.66	0.012
Belching	0.10 ± 0.46	0.56 ± 0.89	0.077
Nausea and vomiting	0.21 ± 0.63	0.12 ± 0.50	0.664
Loss of appetite	0.21 ± 0.42	0.50 ± 0.73	0.152